Stock Analiz

Evotec SE EVO

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$1.58Market cap $562M
Open the interactive analysis →

Evotec SE (EVO) is a healthcare company listed in the US with a market value of about $562M. In the twelve months to September 30, 2026 it had revenue of $792M and net income of -$199M, a net margin of -25.2%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 11% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.

About Evotec

Evotec is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $502M in 2019 to $869M in 2025, growth of about 9.6% a year. It was profitable in 3 of the last 7 years in our data.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • 5-year revenue growth above 8% a year
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.7
P/B0.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-26.8%
Shareholder yield0.0%
Intrinsic value vs. price−98%

Growth and quality

Revenue growth (1 yr)-4.1%
Revenue growth (5 yrs, per year)10.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4.5%
ROIC (5-yr avg.)-0.9%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$792M$869M$828M$863M$801M$700M$615M$502M
Net income-$199M-$114M-$204M-$93M-$187M$244M$8M$43M
Free cash flow-$151M-$101M-$103M-$195M$26M$9M-$67M$12M
EPS (diluted)$-0.56$-0.32$-0.57$-0.26$-0.53$0.69$0.02$0.12
Net margin-25.2%-13.1%-24.6%-10.7%-23.4%34.9%1.2%8.6%
ROIC——-9.1%-2.4%1.1%2.1%3.6%8.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Evotec stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Evotec pay a dividend?

Not currently.

Is Evotec a good stock to buy?

We do not give buy or sell advice. Evotec scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.